Morgan Stanley
ANRO icon

Morgan Stanley’s Alto Neuroscience ANRO Stock Holding History

Morgan Stanley’s Portfolio ANRO Stock Details ANRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.98M Buy
74,940
+6,286
+9% +$145K ﹤0.01% 4855
2026
Q1 		$1.54M Buy
68,654
+3,073
+5% +$57K ﹤0.01% 4917
2025
Q4 		$1.17M Buy
65,581
+4,545
+7% +$57.2K ﹤0.01% 5100
2025
Q3 		$245K Sell
61,036
-3,594
-6% -$11.9K ﹤0.01% 5809
2025
Q2 		$142K Buy
64,630
+17,823
+38% +$42.4K ﹤0.01% 5990
2025
Q1 		$101K Sell
46,807
-155,834
-77% -$558K ﹤0.01% 5998
2024
Q4 		$857K Buy
202,641
+126,480
+166% +$789K ﹤0.01% 5160
2024
Q3 		$871K Buy
76,161
+49,838
+189% +$610K ﹤0.01% 5122
2024
Q2 		$281K Buy
26,323
+13,038
+98% +$170K ﹤0.01% 5529
2024
Q1 		$204K Buy
+13,285
New +$208K ﹤0.01% 5727

Other funds holding ANRO

AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SSC
Spruce Street Capital New York $510M AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Morgan Stanley's ANRO Position: Q2 2026 in Review

Morgan Stanley increased its Alto Neuroscience (ANRO) stake by 9.2% in Q2 2026, buying an estimated $145K and bringing the position to 74,940 shares worth $1.98M. The position accounts for ﹤0.01% of the portfolio, ranked #4855.

Morgan Stanley first reported a position in ANRO in Q1 2024 and has held it in 10 quarters since. 114 funds tracked by Wall St. Rank hold ANRO as of Q2 2026.

  • Morgan Stanley held 74,940 shares of Alto Neuroscience worth $1.98M as of Q2 2026.
  • Morgan Stanley bought 6,286 Alto Neuroscience shares in Q2 2026, an estimated $145K.
  • Alto Neuroscience made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #4855 holding.
  • Morgan Stanley first reported a position in Alto Neuroscience in Q1 2024 and has held it in 10 quarters since.
  • 114 funds tracked by Wall St. Rank held Alto Neuroscience as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.